In addition to their glucose-lowering properties, SGLT-2 inhibitors decrease cardiovascular mortality, heart failure mortality, atrial fibrillation, and heart failure readmissions [6,7,8,9,10,11,12,13]. The gene discussed is SLC5A2; the disease is heart failure.